|We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.|
CHEAPEST Covid 19 Vaccine gem ....
Low valuation of 49 million --has 3x Phase 3 programs with Data in Q4 / and a Covid 19 Vaccine programm with data coming soon ..has potential to move like INO or NVAX ...
Marekt Cap $50 Million
Shares Out 26. 6 M
Soligenix Completes Enrollment in its Pivotal Phase 3 Clinical Trial of SGX942 for the Treatment of Oral Mucositis
Final top-line results expected Q4 2020
SNGX: Q&A on COVID-19 Vaccine Candidate CiVax™…
As a reminder, following the positive topline data presented by the company for SGX-301 in CTCL, we continue to anticipate Phase 3 data for SGX-942 in oral mucositis in the fourth quarter of 2020. The company will also be joining the Russell Microcap Index effective June 29th, 2020, which should help to increase visibility within the investment community. Our current valuation is $12 per share.
|© 2020 Knight Sac Media. Data provided by IEX, Alpha Vantage, Coinbase, Binance, Fintel and CityFALCON News|